ArticleOncogene2019
VEGF
Erratum issuedAbstract read
In one paragraph
Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 49 citations in OpenAlex.
- Deconvoluting the multi-faceted roles of alternative splicing events in cancer: From underlying mechanisms to innovative therapeutics.Acta pharmaceutica Sinica. B · 2026Review
- Alternative Splicing-Mediated Resistance to Antibody-Based Therapies: Mechanisms and Emerging Therapeutic Strategies.International journal of molecular sciences · 2025Review
- The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025Review
- RNA splicing: Novel star in pulmonary diseases with a treatment perspective.Acta pharmaceutica Sinica. B · 2025Review
- Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements.Frontiers in oncology · 2025Review
- Prognostic alternative mRNA splicing in lung adenocarcinoma.Frontiers in oncology · 2025Article
- Alternative Splicing: A Critical Regulator in Human Bone Biology and Tumor Progression.Research (Washington, D.C.) · 2025Review
- A Splice Form of VEGF, a Potential Anti-Angiogenetic Form of Head and Neck Squamous Cell Cancer Inhibition.International journal of molecular sciences · 2024Review
- Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.The EPMA journal · 2024Article
- Development of a predictive model to predict postoperative bone metastasis in pathological I-II non-small cell lung cancer.Translational lung cancer research · 2024Article
- A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update.International journal of molecular sciences · 2024Review
- The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGFHeliyon · 2023Article
- The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy.International journal of molecular sciences · 2022Review
- Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer.Molecular oncology · 2022Article
- Retinopathy of prematurity shows alterations in VegfaPediatric research · 2022Article
- How VEGF-A and its splice variants affect breast cancer development - clinical implications.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Intrinsically disordered proteins play diverse roles in cell signaling.Cell communication and signaling : CCS · 2022Review
- The role of angiogenesis in melanoma: Clinical treatments and future expectations.Frontiers in pharmacology · 2022Review
- FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells.BMC biology · 2021Article
- Vascular normalisation as the stepping stone into tumour microenvironment transformation.British journal of cancer · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
18 authors at 1 institution in 2 countries.
Asma BoudriaINSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Cherine Abou FaycalINSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Tao JiaINSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Stephanie GoutINSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Michelle KeramidasUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Chloé DidierUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Nicolas LemaîtreUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Sandra ManetUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Jean-Luc CollUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.ORCID http://orcid.org/0000-0002-2453-3552
Anne-Claire ToffartUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Denis Moro-SibilotUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Corinne Albiges-RizoUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Véronique JosserandUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Eva FaurobertUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Christian BrambillaUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Elisabeth BrambillaUniversité Grenoble Alpes, Institut Pour l'Avancée des Biosciences, Grenoble, 38041, France.
Sylvie GazzeriINSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France.
Beatrice EyminINSERM U1209, UMR CNRS 5309, Team RNA splicing, Cell Signaling and Response to Therapies, Grenoble, 38042, France. Beatrice.Eymin@ujf-grenoble.fr.
Centre National de la Recherche Scientifique · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor-A (VEGF-A) is highly subjected to alternative pre-mRNA splicing that generates several splice variants. The VEGF
Indexed as
Alternative SplicingAngiogenesis InhibitorsAutocrine CommunicationBevacizumabCarcinoma, Non-Small-Cell LungFemaleHumansIntegrin beta1Lung NeoplasmsMaleNeoplasm ProteinsNeovascularization, PathologicProtein IsoformsReceptors, Vascular Endothelial Growth FactorSignal TransductionVascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabIntegrin beta1Neoplasm ProteinsProtein IsoformsReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AVEGFA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.